CHAPTERS
- 0:00 – 1:14
Agarikon: rare old-growth mushroom and why Stamets considers it a “biodefense” species
Stamets presents Agarikon as a highly rare old-growth polypore with a 2,000+ year history of medicinal use. He connects its conservation to national/international security by framing old-growth forests as reservoirs of potentially critical antiviral biodiversity.
- •Agarikon’s rarity, threatened status, and old-growth habitat dependence
- •Historical references: Dioscorides and Indigenous Northwest pharmacopeia
- •Post-9/11 biodefense interest in antivirals from mushrooms
- •Old-growth forests as “cultural/genomic libraries” worth protecting
- •Importance of fungal biodiversity (mycodiversity)
- 1:14 – 3:15
BioShield testing and building the world’s largest Agarikon culture library
He recounts government antiviral screening where Agarikon ranked among top candidates and the only natural product in the top tier. Stamets explains his long-term effort to collect, culture, and preserve strains as the species declines in the wild.
- •USAMRIID/NIH antiviral assays and early press release (2004)
- •Agarikon activity against poxviruses highlighted as exceptional
- •Investment of millions into collecting and preserving strains
- •Current library size: 107 Agarikon strains across regions
- •Why strain libraries matter as forests disappear
- 3:15 – 5:46
COVID-19 vaccine-adjunct trial: design, dosing, and what they measured
Stamets describes a double-blind, placebo-controlled study evaluating Agarikon + turkey tail mycelium as a short-term supplement around mRNA vaccination. The team measured post-vaccine symptoms and later antibody levels to assess tolerability and immune response durability.
- •Double-blind placebo-controlled design; placebo was rice-only vs mycelium-on-rice
- •Recruitment from vaccination lines; Moderna/Pfizer recipients
- •4-day dosing window concurrent with vaccination
- •Symptom tracking based on CDC/UCSD adverse event lists
- •Physician-facing evidence hub: mushroomreferences.com
- 5:46 – 9:03
Results: reduced post-vaccine adverse symptoms and the cytokine-storm concern
They discuss how the trial showed markedly fewer self-reported adverse symptoms in the mushroom group versus placebo. Stamets addresses FDA concerns about immune overstimulation and frames findings as anti-inflammatory cytokine upregulation rather than triggering a cytokine storm.
- •Symptom reduction peak days 2–3 compared to placebo
- •FDA safety concerns: potential cytokine storm from immunostimulants
- •Observed increase in anti-inflammatory cytokines (IL-1RA, IL-10)
- •Why reducing side effects could lower vaccine hesitancy
- •Broader context: inflammation as a driver of many adverse responses
- 9:03 – 12:07
Unexpected finding: antibody persistence and “immune readiness” six months later
Stamets explains the surprising six-month follow-up showing stronger antibody levels in the mushroom group despite only four days of dosing. They discuss the concept that raising baseline immune readiness could improve vaccine effectiveness and reduce variant-driven immune escape risk.
- •Six-month follow-up with high return rate (nearly all participants)
- •Virus-naive participants to avoid confounding from infection immunity
- •Short dosing correlated with stronger antibody reservoir later
- •Hypothesis: immunologically depressed people may respond poorly to vaccines
- •Potential public health implication: reduce viral replication and evolution
- 12:07 – 14:28
Mechanisms and “entourage effects”: mycelium vs fruiting bodies, and immune cell changes
Pressed on mechanisms, Stamets emphasizes multi-pathway “entourage” effects and immune crosstalk. He references turkey tail cancer research and stresses that mycelium (not just fruiting bodies) appears central to immune modulation and inflammation control.
- •Entourage model: immune activation plus inflammation throttling
- •Turkey tail phase-1 breast cancer study and immune cell changes
- •Immune players: NK cells, macrophages, cytotoxic T-cells
- •Mycelium-on-rice as the studied material (not primarily fruit bodies)
- •Cautionary stance: immunostimulation risks require careful study
- 14:28 – 29:51
Viral “storms,” bird flu jumping species, and why community immunity matters
They pivot to emerging zoonotic threats, focusing on H5N1 bird flu detected in cattle and the fear of a jump to pigs. Stamets connects industrial farming, biodiversity loss, and ecosystem edges to increasing pandemic frequency and severity.
- •“Viral storms” driven by factory farming and ecosystem disruption
- •H5N1 in cattle as an unprecedented development; multi-state spread
- •Why pigs represent a key risk step toward human adaptation
- •High estimated mortality rates for human H5N1 cases
- •Motivation for strengthening baseline immunity to reduce spread
- 29:51 – 37:30
Strain variation: why some Agarikon strains show activity and others don’t
Stamets explains that strain-to-strain differences are substantial, with some strains showing no antiviral activity in early programs. He compares this to penicillin’s discovery and the need to find “super strains” through sequencing and broader screening.
- •BioShield: only some submitted strains showed antiviral activity
- •Different targets: activity against flu (RNA) vs pox (DNA) viruses
- •Whole-genome sequencing underway; identification of clades/lineages
- •Analogy to Mary Hunt’s cantaloupe and scaling penicillin production
- •Goal: correlate genetics with potency and prioritize candidates
- 37:30 – 40:54
Conservation stories: giant century-old Agarikon and what its resilience implies
Stamets shares field stories of rescuing Agarikon by taking small tissue samples and preserving cultures. A photo of an enormous, century-old specimen prompts discussion of its resistance to rot and its potential antifungal/antibacterial/antiviral defenses.
- •Tissue sampling and culture as a conservation strategy
- •Examples of losses from storms, fires, logging—and successful preservation
- •Agarikon longevity (100+ years) and rot resistance as a biological clue
- •Agarikon as a nexus: antiviral, antibacterial, and antifungal potential
- •Broader point: humans are closely related to fungi; fungi produce many antibiotics
- 40:54 – 56:09
Amanita muscaria & pantherina: effects, folklore, and a cautionary “heroic” story
The conversation shifts to Amanita mushrooms, their uneven psychoactive reputation, and cultural myths. Stamets recounts intense effects from Amanita pantherina, including repetitive motion syndrome and dangerous impairment, underscoring risks and variability.
- •Muscimol/ibotenic acid effects vs psilocybin-type experiences
- •Muted visual spectrum, sleepiness, and muscarinic symptoms (salivation)
- •Repetitive motion syndrome and loss of control as key danger
- •Long personal anecdote demonstrating impairment and public risk
- •Link to berserker folklore and why species variability matters
- 56:09 – 1:11:24
Funding and credibility: building a research company, skepticism, and scientific “hubris”
Rogan and Stamets discuss why mushroom science is still underfunded and often dismissed as fringe. Stamets shares the hard early years building his company and argues that traditional knowledge and biodiversity deserve more scientific humility and investment.
- •Research constraints as a small company; reliance on university partnerships
- •Argument for large-scale funding to explore strain diversity and new benefits
- •Personal story: financial hardship, persistence, and growth to 150 employees
- •Science vs tradition: lost knowledge, documentation limits, and humility
- •Biodiversity as a critical resource for medicine and resilience
- 1:11:24 – 1:25:19
Microdosing research and the “Stamets Stack”: app-based citizen science results
Stamets presents observational research powered by the microdose.me app and a large participant pool, including many non-microdosers. He highlights results suggesting mood improvements and, more notably, measurable psychomotor gains in a finger-tapping test from the full stack.
- •Citizen-science design with large control group participation
- •Nature Scientific Reports publication and later correction due to a typo
- •Tap test as an objective measure vs subjective mood/self-report
- •Stamets Stack: low-dose psilocybin + lion’s mane + flushing niacin
- •Large observed tap-rate gains in one month for stack users
- 1:25:19 – 1:32:03
How might the Stack work? Vasodilation, nerve growth factors, and testing performance gains
They dig into possible mechanisms: niacin as vasodilator countering psilocybin vasoconstriction, lion’s mane compounds supporting myelin and NGF pathways, and psilocybin’s neuroplastic effects. Rogan explores broader athletic and reaction-time testing ideas and the need for longer follow-ups.
- •Niacin rationale: vasodilation and peripheral nerve endpoints
- •Lion’s mane: erinacines, NGF stimulation, myelin support
- •Psilocybin: neuroplasticity/neurogenesis hypotheses
- •Need to extend studies to 90 days and broaden objective tasks
- •Challenges: uncontrolled sourcing/doses and other confounders in observational data
- 1:32:03 – 1:54:59
Policy and society: psilocybin legalization, law enforcement, fentanyl, and AI ethics
The discussion expands to drug policy, PTSD relief among veterans and police, and why decriminalization is accelerating. They connect mental health, inflammation, and social stability, then pivot to AI as a powerful tool that still lacks human qualities like intentional kindness.
- •Prediction: rescheduling/legalization trajectory (political timing)
- •Law enforcement and veterans adopting psychedelics for trauma recovery
- •Fentanyl crisis as higher priority than psilocybin enforcement
- •Debate: decriminalization vs legalization and safe administration centers
- •AI’s promise for medicine vs limits in modeling human generosity and meaning
- 1:54:59 – 2:08:28
Ancient psychedelics: Egypt mushroom iconography, blue lotus synergy, and ‘blue juice’
Stamets argues that multiple ancient cultures likely used psychoactive mushrooms, pointing to Egyptian art and Mesoamerican mushroom stones. He introduces ‘blue juice’ from psilocybin extraction, ties it to Dune’s ‘spice’ mythology via Frank Herbert, and discusses blue lotus compounds and effects.
- •Egyptian temple imagery interpreted as mushrooms and blue lotus pairing
- •Call for DNA evidence from archaeological sites; reward for proof concept
- •‘Blue juice’ extraction and preservation methods (water/honey)
- •Frank Herbert/Dune inspiration linked to psilocybin imagery and ideas
- •Blue lotus: aporphine alkaloids; reported alertness and synergy claims
- 2:08:28 – 2:32:34
Ethics, re-indigenization, and end-of-life care: why Stamets won’t “provide” mushrooms
Stamets emphasizes ethics and structure around powerful psychoactive medicines, describing himself as a mycologist rather than a therapist. He discusses re-indigenization of ancestral practices, supportive end-of-life programs, and how reduced fear and stress may improve immune function.
- •Ethical boundary: ‘nature provides, I don’t’—refusal to supply others
- •Need for ceremonial/therapeutic frameworks honed by Indigenous traditions
- •Re-indigenization examples: Druids, Egyptian alchemists, ancestral roots
- •Roots to Thrive end-of-life model and profound fear-of-death reduction
- •Link between reduced anxiety/inflammation and improved immunity
